

Table 3M

MORTALITY in all available unconfounded randomized trials of post-mastectomy radiotherapy (logrank analyses of yearly rates, excluding deaths after 1 Sep 1985)

Study	Study name	Systemic adjuvant, both arms	Age <50 at entry			Age 50+ at entry			Sum of statistics for young & old				
			Deaths entered	Statistics	O-E Var	Deaths entered	Statistics	O-E Var	O-E Var	O-E Var	Chi - sq.		
64B 1	Oslo X-ray	--	37/111	38/108	- 0.7	15.8	105/174	95/159	0.5	31.3	*	*	
64B 2	Oslo Co-60	--	33/90	32/101	1.6	13.6	78/188	71/184	1.9	28.3	3.3	89.0	0.1
69A	Heidelberg XRT	--	12/20	12/17	- 0.8	4.8	51/64	28/41	5.5	13.2	4.7	17.9	1.2
70A 1	Manchester RBS1	--	44/132	55/137	- 5.4	21.4	125/223	128/222	- 1.8	46.1	- 7.2	67.5	0.8
70B	King's/Cambridge	--	209/496	201/482	1.4	86.8	467/880	476/942	13.1	182.4	14.6	269.2	0.8
71B	Stockholm A	--	24/91	31/83	- 5.3	12.3	95/232	101/238	- 1.4	41.1	- 6.7	53.4	0.8
71C	NSABP B-04**	--	43/117	50/118	- 6.7	19.1	102/235	120/247	1.3	47.4	- 5.4	66.5	0.4
72A	WSSA Glasgow	--	9/31	24/48	- 5.3	7.0	39/63	43/75	1.4	14.3	- 3.9	21.3	0.7
73A	Wessex	--	9/26	15/24	- 4.1	4.9	18/45	25/51	- 2.8	9.0	- 6.9	13.9	3.5
73C 1	Mayo Clinic	--	0/0	1/3	0.0	0.0	1/5	3/5	- 1.2	0.8	*	*	

73C 1	Mayo Clinic	CFPr	1/ 3	2/ 2	- 0.9	0.6	4/ 8	6/ 8	- 1.6	1.7	*	*
73C 2	Mayo Clinic	CFPr	2/ 5	2/ 2	1.0	0.7	30/ 62	23/ 56	1.8	11.3	*	*
73C 3	Mayo Clinic	CFPr	5/ 12	4/ 15	1.1	2.0	3/ 4	0/ 2	1.1	0.6	*	*
73C 4	Mayo Clinic	CFPr	7/ 17	10/ 23	- 0.9	3.8	3/ 5	2/ 4	0.6	0.9	- 0.9	22.3 0.0
74B	Edinburgh I	--	18/ 73	15/ 65	0.8	7.6	32/100	35/110	1.0	14.6	1.8	22.2 0.2
75K	Piedmont OA	Mel	11/ 25	8/ 29	1.9	4.3	23/ 51	22/ 41	- 1.9	9.6	*	*
75K	Piedmont OA	CMF	15/ 26	6/ 24	4.4	4.5	22/ 43	20/ 42	0.5	8.9	4.9	27.3 0.9
76A 2	SECSG 1	CMF	6/ 21	13/ 27	- 2.6	4.2	12/ 28	17/ 34	- 0.6	5.9	*	*
76A 3	SECSG 1	CMF	13/ 33	8/ 28	3.0	4.4	8/ 45	14/ 40	- 3.9	4.9	- 4.0	19.4 0.8
76C	Glasgow	CMF	16/ 47	9/ 33	0.6	5.3	28/ 65	33/ 69	- 0.6	13.0	0.0	18.3 0.0
78A 1	S Swedish BCG C		17/ 98	16/ 91	0.4	7.9	9/ 49	11/ 48	- 1.0	4.7	*	*
78A 2	S Swedish BCG Tam		0/ 1	0/ 0	0.0	0.0	43/238	51/243	- 5.6	22.0	- 6.3	34.6 1.1
78D 4	Scottish D	Tam	2/ 8	1/ 7	0.4	0.7	5/ 16	2/ 16	1.4	1.7	*	*
78D 4	Scottish D	--	0/ 6	0/ 7	0.0	0.0	6/ 17	2/ 16	2.0	1.9	3.8	4.3 3.3
78G 1	CCABC Canada	CMF	6/ 23	4/ 29	0.9	2.3	0/ 8	2/ 6	- 1.0	0.5	*	*
78G 1	CCABC Canada	CMF+Oo ph	3/ 30	3/ 27	0.0	1.4	0/ 5	0/ 6	0.0	0.0	*	*

78G 2	CCABC Canada	CMF	0/12	1/9	0.7	0.2	0/4	0/0	0.0	0.0	*	*
78G 3	CCABC Canada	CMF	14/61	10/54	1.2	5.5	2/11	4/6	2.4	1.0	2.1	11.0 0.5
82B	Danish BCG 82b	CMF	10/165	7/144	1.3	4.1	6/59	8/68	0.5	3.3	0.7	7.3 0.1
82C 1	Danish BCG 82c	Tam	0/3	0/1	0.0	0.0	19/229	18/232	0.5	8.8	0.5	8.8 0.0
84A 2	BMFT 03 Germany	CMF	0/7	0/4	0.0	0.0	0/15	0/19	0.0	0.0	0.0	0.0 0.0
TOTAL: 19 TRIALS***	+/-		566/1790	578/1742	15.4	245.0	1336/3171	1360/3230	6.4	529.2	774.0	0.1
(Odds reduction ± SD)						(6% ± 6)				(-1% ± 4)		(1% ± 4)

Approximate chi-squared test for heterogeneity on 17 degrees of freedom = 15.2; 2P>0.1; NS.

* Items marked with an asterisk contribute to totals directly below them.

** Published results (3), since individual patient data not available.

Data from about 10 randomized radiotherapy trials that began before 1.1.1985 were not available in 1985, and are not included here. Data from one large trial (Manchester Christie) *** have been excluded because of non-standard randomization: inclusion would have changed the "sum of statistics" to -10.5, 955.0, 0.1 & 1% ± 3